NPCE stock icon

Neuropace
NPCE

$6.71
0.3%
 

About: NeuroPace Inc is a commercial-stage medical device company focused on transforming the lives of people suffering from epilepsy by reducing or eliminating the occurrence of debilitating seizures. It derives substantially all its revenue from the sales of RNS System to hospitals facilities (typically Level 4 CECs) that implant RNS System.

Employees: 181

0
Funds holding %
of 6,702 funds
0
Analysts bullish %
of 8 analysts
News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

285% more call options, than puts

Call options by funds: $381K | Put options by funds: $99K

260% more first-time investments, than exits

New positions opened: 18 | Existing positions closed: 5

200% more funds holding in top 10

Funds holding in top 10: 0 [Q4 2023] → 2 (+2) [Q1 2024]

67% more repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 12

32% more funds holding

Funds holding: 41 [Q4 2023] → 54 (+13) [Q1 2024]

23% more capital invested

Capital invested by funds: $143M [Q4 2023] → $176M (+$33.5M) [Q1 2024]

5.61% less ownership

Funds ownership: 52.75% [Q4 2023] → 47.15% (-5.61%) [Q1 2024]

Research analyst outlook

8 Wall Street Analysts provided 1 year price forecasts over the past 6 months

Low target
$12
79%
upside
Avg. target
$17
153%
upside
High target
$22
228%
upside

8 analyst ratings

positive
75%
neutral
25%
negative
0%
Cantor Fitzgerald
Ross Osborn
168%upside
$18
Overweight
Reiterated
9 May 2024
Wells Fargo
Lawrence Biegelsen
198%upside
$20
Overweight
Upgraded
14 Mar 2024
JP Morgan
Robbie Marcus
153%upside
$17
Overweight
Maintained
12 Mar 2024
Cantor Fitzgerald
Ross Osborn
168%upside
$18
Overweight
Maintained
6 Mar 2024
Morgan Stanley
Drew Ranieri
94%upside
$13
Equal-Weight
Maintained
6 Mar 2024

Financial journalist opinion